Difference between revisions of "Fluvoxamine-duloxetine"

From Psychiatrienet
Jump to: navigation, search
Line 11: Line 11:
 
* Fluvoxamine inhibits the metabolism of duloxetine through CYP1A2.
 
* Fluvoxamine inhibits the metabolism of duloxetine through CYP1A2.
 
* {{theorSS}}
 
* {{theorSS}}
 +
}}

Revision as of 08:33, 3 August 2009

Fluvoxamine
Type Antidepressant
Group SSRI
links
Medscape Fluvoxamine
PubChem 5324346
PubMed Fluvoxamine
Kompas (Dutch) Fluvoxamine
Wikipedia Fluvoxamine
Duloxetine
Type Antidepressant
Group SNRI
links
Medscape Duloxetine
PubChem 60835
PubMed Duloxetine
Kompas (Dutch) Duloxetine
Wikipedia Duloxetine

Switch medication from fluvoxamine to duloxetine.[1] [2]

Nietinrijdenbord.png Stop fluvoxamine
  • Before day 0: gradually reduce dosage of fluvoxamine to a maximum of 50 mg/day.
  • Day 1: stop fluvoxamine.
Eenrichtingbord.png Start duloxetine
  • Day 5: start duloxetine 30 mg/day.
  • Day 14: increase administration of duloxetine to 60 mg/day.
Infobord.png More information
  • Fluvoxamine inhibits the metabolism of duloxetine through CYP1A2.
  • Occurrence of the serotonin syndrome is not likely, but theoretically possible, so caution is necessary.
  1. Switches are based on literature references on this page and expert opinions of the authors. The authors have used pharmacokinetic and receptor affinity properties to determine the switch schedules
  2. Stahl, S. M. (2013). Stahl's essential psychopharmacology: Neuroscientific basis and practical applications (4th ed.). Cambridge University Press.
The editors of psychiatrienet.nl take the greatest care to provide up-to-date and accurate information on this site. Nevertheless, mistakes and omissions cannot be entirely excluded. No rights devolve from the information provided. The editors and other providers of information to this site accept no responsibility for the content of this site or for the information provided therein; neither do they accept responsibility for possible damages which may derive from the use of the information on this site or from the linked sites. The editorial board accepts no responsibility for the content of the (linked) sites, for access to them, or for the products and services on these sites, nor for the occurrence of errors, viruses, and/or disruptions in service.